Stemness has been associated with worse patient outcomes, immunosuppressive TME, and treatment resistance in CRC patients, thus indicating that decreased HOXA5 expression and its relationship to stemness could identify patients at risk [143]. This evidence concerns the gene HOXA5 and colorectal carcinoma.